Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Big Pharma plans to...

    Big Pharma plans to turn rural India into a cash cow

    Written by Ruby Khatun Khatun Published On 2017-08-06T09:20:52+05:30  |  Updated On 6 Aug 2017 9:20 AM IST

    By Ari Altstedter


    First, foreign food brands flooded India with chips, cookies and soft drinks that fundamentally changed the nation’s eating habits. Now, Big Pharma wants to cash in on an upsurge in cases of diabetes and heart disease in the country’s most distant corners.


    Global pharmaceutical companies, from Indianapolis-based Eli Lilly & Co. to Switzerland’s Novartis AG, are heading into smaller cities and rural areas to learn about the healthcare needs of about 70 per cent of the population. These remote regions of the developing world are the final frontier for the international drug industry.


    In the farming village of Thana Kalan outside New Delhi - where buffalo roam narrow streets and the scent of cow dung used for fuel hangs faintly in the air - Ajit Singh had never heard of diabetes. That was until community health workers showed up at the door and warned him and his wife they were at high risk of it.


    The Singh's were part of a free door-to-door screening program funded by Eli Lilly, which is among the world’s biggest makers of diabetes medicines. Even though families like theirs might only start off with cheap generic drugs the hope is that they will be more likely to shift to pricier brands as their incomes rise. And if Big Pharma can figure out a way to serve these patients while turning even a slim profit, the sheer numbers could mean a huge payout down the road.


    "Companies are interested in taking a longer-term stance and understanding the characteristics of these markets and positioning themselves in a way that could help them down the line capture market share," said Sebastien Mazzuri, a director with consulting firm FSG, who specializes in developing pharmaceutical markets.


    Foreign Brands


    India’s two decades of economic growth has attracted consumer brands such as Coca-Cola Co. and Unilever. Rising incomes have powered increased motor vehicle ownership and also greater demand for processed foods. Active lifestyles were replaced by sedentary ones. In recent years, the country has been home to about 69 million diabetics, according to the International Diabetes Federation. China has about 110 million diabetes patients.


    Over the last five years, virtually all the growth in the volume of medicines sold globally has been in the largest developing markets, while the developed world stagnated, according to a report last year by Quintiles IMS Holdings Inc. Among the fastest growing were China and India.


    Chinese spent $116.7 billion on medicine in 2016, a figure that could reach as much as $170 billion in 2021. Spending in India is forecast to grow at an even faster rate-from $17.4 billion to as high as $30 billion over the same time frame.


    In rural India and China, where health-care access ranges from spotty to non-existent, there are almost 1.5 billion people, many of whom have never been tested for cholesterol levels, diabetes or heart disease.


    The Lilly-funded pilot program that screened Singh, run by the non-profit Public Health Foundation of India, sends community health workers house to house in two mid-sized Indian cities and the surrounding countrysides with tablet computers programmed to screen people for diabetes and hypertension. It also raises awareness of the diseases and is training local health workers to better diagnose and treat them.


    David Ricks, Lilly’s chief executive officer, says such programs represent a long-term business opportunity and let the company gain a better understanding of the challenges of medicine in the developing world, such as refrigeration and supply-chain setup. “By running these pilots, we can learn and experiment,” he says. “Our projects are working on all of those angles to try and stand up, within difficult environments, better ways to treat diabetes.”


    Lifestyle Diseases


    Meanwhile, Merck & Co., India’s Sun Pharmaceutical Industries Ltd. and GlaxoSmithKline Plc. are funding programs, also run by PHFI, that train general practitioners to treat similar lifestyle diseases in small Indian urban centers, where there’s unlikely to be a specialist.


    Since 2007, Swiss health giant Novartis AG has run a "for-profit social initiative" designed to bring health care to rural India by dispatching doctors to villages and distributing affordable medicines through local pharmacies. The program has since expanded to Kenya, Indonesia and Vietnam.


    It’s a way of "building health ecosystems" that will eventually help Novartis grow in untapped market segments, Jawed Zia, country president of Novartis India, said in an e-mailed statement. "This is simply good business sense."


    Sailesh Mohan, an associate professor with PHFI, who is running the Lilly-funded pilot project that screened Singh, said he’s had complete independence in the execution of his study, and nothing in the pilot recommends any particular company’s products. He said Lilly’s funding had no strings attached and patient data is kept confidential.


    The ultimate goal of these pilot programs is to develop cost-effective strategies that can be adopted by government and deployed more broadly, Mohan said. "Obviously, if they manage to get more people to be aware of their condition, to be evaluated, confirmed, and then put on treatment, those companies are going to benefit."


    Playstation


    Over the course of this decade about 28 million households in rural India will have climbed out of the lowest income class, according to a report by consultancy McKinsey & Co.


    From his sons’ PlayStation 3 to the Korean-made car outside, Ajit Singh’s home is full of evidence of the prosperity that’s changed life in his largely rural state of Haryana. Singh doesn’t work in the village, but instead commutes to Delhi each morning where he works for the central government, drafting maps of the local area, for a monthly income of about $1,200.


    The community health worker has been going through a long list of changes to his lifestyle and diet Singh will have to make to ensure he stays healthy. "Can I consume tea?" the 56-year-old asked, bemused and a little exasperated.


    Nevertheless, he plans to get tested for diabetes. His wife, Sudesh Devi, did after the health worker advised it, and found out she’s diabetic. While a shop across the street is adorned with displays of potato chips, sweets and Indian snacks, the couple say they’ve been trying to eat healthy.


    To get treated, his wife didn’t bother waiting in line at a public health facility, but paid for the convenience of a private hospital. Singh said he’ll do the same. They can afford it.

    Ajit SinghBig Pharmacash cowDavid Ricksdiabetesdiabetes medicinesEli LillyFosun PharmaceuticalGlaxoSmithKlineHealthcareheart diseaseInternational Diabetes FederationMerckNovartis AGplansrural IndiaSailesh MohanSebastien Mazzuriturn
    Source : Bloomberg

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok